Joint & Cartilage
Early to moderate osteoarthritis of the knee, hip and shoulder. Cartilage defects and persistent joint pain following injury.
See pathway
AGATHISHA
INSTITUTE OF STEMCELL AND
REGENERATIVE MEDICINE
Home/Clinical Care
A clinical service that only offers what the evidence supports — and tells you plainly when it does not.
Before Anything Else
Regenerative medicine has a marketing problem. Clinics around the world offer cell therapy for conditions where the evidence simply does not exist, and patients pay for hope rather than treatment.
We assess every referral against the published evidence for your specific indication. Where that evidence is strong, we will say so and explain what outcome you can reasonably expect. Where it is thin or absent, we will tell you that too — and we will not treat you.
Roughly one in four people who consult us are advised against therapy. We consider that a feature of the service, not a failure of it.
1 in 4advised against therapy
Clinical Services
Indications where our own outcome data, and the wider literature, support intervention.
Early to moderate osteoarthritis of the knee, hip and shoulder. Cartilage defects and persistent joint pain following injury.
See pathwayNon-union and delayed-union fractures, critical-size defects, and bone loss following surgical resection.
See pathwayChronic tendinopathy, partial tears and post-surgical soft tissue healing that has plateaued.
See pathwayChronic non-healing wounds, diabetic foot ulceration and hypertrophic scarring.
See pathwayStructured rehabilitation alongside biologic therapy, with physiotherapy and pain management integrated from day one.
See pathwayIndependent review of a regenerative therapy you have been offered elsewhere. We will tell you what the evidence actually says.
Request reviewThe Pathway
Every cost, risk and expected outcome is on paper before you are asked to consent to anything.
A detailed review of your history, imaging and goals — and an honest assessment of whether therapy is appropriate at all.
Imaging, laboratory and where indicated molecular assessment, to establish a measurable baseline we can compare against later.
A protocol document setting out expected outcomes, risks, alternatives and total cost. You take it away and read it before deciding.
Harvest, processing and administration carried out in GMP-grade facilities by the treating clinician, usually within a single day.
Structured rehabilitation with outcome measurement at 6 weeks, 3 months, 6 months and annually for five years.
Send us your history and imaging. Our clinical coordinators will tell you honestly whether an assessment is worth your time.